In September 2017, the 18th Congress of the European Society for Organ Transplantation (ESOT) took place in the beautiful city of Barcelona, Spain.
Results from the Novartis-sponsored clinical trials in patients who were recipients of living donor liver transplants (H2307) or de novo kidney transplants (TRANSFORM) were presented at the Congress. Slides from four presentations are available for you to view below.
This slide presentation discusses the results of the H2307 study into whether the use of everolimus with reduced tacrolimus provides comparable efficacy versus standard tacrolimus therapy following living donor liver transplantation.
Learn more about the results from the TRANSFORM clinical trial surrounding the rate of infection and adverse events in patients taking everolimus and reduced calcineurin inhibitor versus mycophenolate and standard calcineurin inhibitor.
The efficacy and safety outcomes of the TRANSFORM study at month 12 are presented here, discussing the study design, objectives, patient demographics and endpoints.